Our Message to Patients
At ACEA, we are driven by our passion for discovering and developing innovative medicines that can significantly improve the lives of patients with life-threatening diseases.
Our team is developing a range of precision medicines including targeted therapies and immunotherapies which target the diverse underlying causes of a disease. These drug candidates are designed to inhibit altered (mutated) or overactive proteins in the body that are implicated in specific disease processes. Our knowledge of cutting-edge molecular testing enables us to adopt a patient-centric approach to our research, designing clinical trials that are focused on individuals who are most likely to benefit from these treatments.
Several of our potential new medicines are currently being tested in clinical trials in the United States, Europe, and China for the treatment of COVID-19, lung cancer, lymphoma, and systemic lupus erythematosus (SLE).
Click an icon to learn more.
Clinical Trial Participation
Clinical trials are essential to ensure new drugs provide patients with safe and effective treatments.
Individuals who participate in a clinical trial make a crucial contribution to the discovery of new, more effective medicines, thereby improving the health and wellbeing of patients in the future. Participation in clinical trials is entirely voluntary. While clinical trials are typically recommended to patients by their treating physician, it is essential for individuals to be aware of potential opportunities to receive a life-changing drug as well as to contribute to improvements in the scientific understanding of their disease.
The results from clinical trials are submitted to independent regulatory agencies such as the US or National Medical Products Administration of China (NMPA), who scrutinize the data to ensure all approved new medicines are safe and effective.
If you are interested in participating in one of our trials, the information is as below:
Phase 1B Study
Double-Blind, Randomized, Placebo-Controlled Study of the Safety, Pharmacokinetics and Pharmacodynamics of AC0058TA in Patients with Systemic Lupus Erythematosus (SLE)